Ensaios Clínicos com Recrutamento Encerrado

O Hospital da Luz Lisboa já realizou diversos ensaios clínicos. Saiba quais.

Clique na lista seguinte e escolha a área de ensaios clínicos com recrutamento encerrado que pretende conhecer. 

  • ASMA

    • Ensaio clínico TRIGGER

    “A 52 week, randomized, double blind, multinational, multicentre, active controlled, 3-arm parallel group trial comparing CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) alone or on top of open-label tiotropium 2.5 µg Respimat® in patients with asthma uncontrolled on high doses of inhaled corticosteroids in combination with long-acting ß2-agonists.”

    Para mais informações:


    • Ensaio clínico Neratinib

    “A Phase 3, randomized, open-label, two-arm study of neratinib plus paclitaxel Versus trastuzumab plus paclitaxel as first-line treatment for ErbB-2-positive locally recurrent or metastatic breast cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007803-10/PT 

    • Ensaio clínico D-CARE

    “A randomized, double-blind, placebo-controlled, multi-center Phase 3 study of denosumab as adjuvant treatment for women with early-stage breast cancer at high risk of recurrence”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011299-32/PT 

    • Ensaio Clínico MK8669-064

    "A Phase 2 randomized trial of the combination of ridaforolimus and exemestane, compared to ridaforolimus, dalotuzumab and exemestane in high proliferation, estrogen receptor positive breast cancer patients"

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000335-11/PT  

    • Ensaio clínico MO28048 (SafeHer)

    “A phase III prospective, two-cohort non-randomized, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as adjuvant therapy in patients with operable Her2-positive early breast cancer [SafeHer study]”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005328-17/PT

    • Ensaio clínico MO28231

    “A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy-based treatment”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001628-37/PT

    • Ensaio clínico MO28047 (PerUse)

    “A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent) breast cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005334-20/PT

    • Ensaio clínico NSABP FB-7

    “A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer: NSABP FB-7”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004391-35/PT

    • Ensaio clínico SOLTI-1007

    “A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000394-23/PT

    • Ensaio clínico ABI-007-MBC-001

    “A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly nab®-Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin as First Line Treatment in Subjects with ER, PgR, AND HER2 Negative (Triple Negative) Metastatic Breast Cancer”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000113-20/PT

    • Ensaio clínico MO28230

    “Phase I study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced/metastatic gastric cancer patients, followed by a randomized, open-label phase II study of trastuzumab emtansine and capecitabine versus trastuzumab emtansine alone in HER2-positive metastatic breast cancer”.

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-001547-46/PT


    A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001931-36/PT

    • Ensaio clínico MANTA

    A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor Positive Advanced or Metastatic Breast Cancer.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002403-34/PT

    • Ensaio Clínico METAPHER

    A multicenter, open-label, single-arm safety study of Herceptin® SC in combination with PERJETA® and docetaxel in treatment of patients with her2-positive advanced breast cancer (metastatic or locally recurrent). 

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001458-40/PT

    • Ensaio clínico SANDPIPER 

    A phase III, double-blind, placebo-controlled, randomized study of taselisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003185-25/PT

    • Ensaio clinico NALA

    A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting.

    Mais informações em: https://clinicaltrials.gov/ct2/show/NCT01808573?term=PUMA-NER-1301&rank=1

    • Ensaio clínico CompLEEment 1:

    “An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.”

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003467-19/PT

    •  Ensaio clínico PALLAS:

    A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005181-30/PT



    • Ensaio clínico Millennium C21004 

    “A Phase 3, randomized, double-blind, multicenter trial comparing Orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer”

    Para mais informações: 

    • Ensaio clínico Millennium C21005 – Recrutamento encerrado

    A Phase 3, randomized, double-blind, multicenter trial comparing orteronel (TAK 700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or following docetaxel-based therapy

    Para mais informações: 

    • Ensaio clínico 212082PCR3011

    “A Study of ZYTIGA and Prednisone with Androgen Deprivation Therapy (ADT) compared to ADT Alone in men newly Diagnosed (within the previous 3 months) with High-Risk, Metastatic Prostate Cancer”

    Para mais informações:

    • Ensaio clínico VIABLE

    “A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy”

    Para mais informações:

    • Ensaio clínico ARAMIS

    “A multinational, randomized, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer”

    Para mais informações:


    • Ensaio clínico E7080-G000-303

    “A multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial of E7080 in 131I- refractory differentiated thyroid cancer”

    Para mais informações: 


    • Ensaio clinico TAS-102-302

    Randomized, Double-Blind, Phase 3 Study Evaluating TAS-102 plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Metastatic Gastric Cancer Refractory to Standard Treatments.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002683-16/PT



    • Ensaio clínico MK3475-18A

    Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181).

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002782-32/PT



    • Ensaio clínico Trinova

    “A Phase 3, randomized, double-blind trial of weekly paclitaxel plus AMG 386 or placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or Fallopian tube cancers”

    Para mais informações:

    • Ensaio clínico LumeOvar

    “Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer”

    Para mais informações: 


    • Ensaio clínico NEPTUNE

    A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002197-21/PT

    • Ensaio clínico M16-289 TAHOE

    “A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003726-17/PT


    • Ensaio clínico APACT

    “A Phase 3, multicenter, open-label, randomized study of nab-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma.”

    Para mais informações:

    • Ensaio Clínico CanStem111P

    A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004359-57/PT


    • Ensaio clínico XL184-308

    “A study evaluating cabozantinib (XL184) versus everolimus in patients with a form of kidney cancer that has progressed after treatment with another therapy”

    Para mais inrormações:


    • Ensaio clínico GARDENIA

    “Phase III, randomized, multicenter double-blind, double-dummy study to evaluate the efficacy and safety of Etrolizumab compared with Infliximab in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors.”

    Para mais informações:



    • Ensaio clínico AZURE

    An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD).

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000120-33/PT



    • Ensaio clínico Carolina

    “A multicentre, international, randomised, parallel group, double blind study to evaluate cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The CAROLINA Trial.”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-013157-15/PT 

    • Ensaio clínico C-SCADE

    “A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk.”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-016178-33/PT   

    • Ensaio clínico BIAsp-3963

    “A 24 week randomised, open label, 3 parallel-group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metformin in insulin naïve type 2 diabetic subjects inadequately controlled on sitagliptin and metformin”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004930-33/PT 

    • Ensaio clínico SUSTAIN 

    “Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004827-19/PT  

    • Carmelina

    “A Phase 4 multicenter, randomized, double blind, placebo-controlled study to investigate the impact of long-term treatment with linagliptin on cardiovascular (CV) outcomes in a selected population of patients with type 2 diabetes mellitus and high CV risk.”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004148-23/PL

    • Ensaio clínico FIDELIO

    “A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000990-11/PT

    • Ensaio clínico FIGARO

    “A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000950-39/PT


    • Ensaio clínico REVOLVE

    “A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.”

    Para mais informações:



    • Ensaio Clínico COMB157G2302

    A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005419-33/PT


    • Ensaio clínico 1220.30

    “A Phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection”

    Para mais informações: 

    • Ensaio clínico 1220.48

    “A Phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-a (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment”

    Para mais informações: 


    • Ensaio clínico BAY94-8862/14564

    “Phase IIb safety and efficacy study of different oral doses of BAY 94-8862 in subjects with worsening chronic heart failure and left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease alone”

    Para mais informações:

    • Ensaio clínico RELAX AHF EU

    “A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.”

    Para mais informações:

    • Ensaio clínico COMMANDER HF

    “A randomized, double-blind, event-driven, multicenter study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an episode of decompensated heart failure”.

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000046-19/PT  

    • Ensaio clínico Dal-Gene

    “A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial.”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003895-65/PT

    • Ensaio clínico TRANSITION

    “A multicenter, randomized, open label, parallel group study comparing pre-discharge and post-discharge treatment initiation with LCZ696 in heart failure patients with reduced ejectIon-fraction hospitalized for an acute decompensation event (ADHF)”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003266-87/PT

    • Ensaio clínico PANACHE

    A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure and preserved ejection fraction

    Mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004062-26/PT


    • Ensaio clínico CL3-20098-073

    “Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering major depressive disorder. 
    A 3-week, randomised, double then single-blind, controlled, parallel groups, international, multicentre safety study with a 5-week open extension period.”

    Para mais informações: 

    • Ensaio clínico CL3-20098-062

    Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with major depressive disorder. A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.

    Para mais informações:

    • Ensaio clínico RUBY

    “A randomized, 6-week, multicentre, open-label, rater-blinded parallel group study comparing Quetiapine extended release monotherapy and augmentation with lithium augmentation in patients with treatment resistant depression” 

    Para mais informações: 


    • Ensaio clínico CATCH

    “Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT”

    Para mais informações:


    • Ensaio clínico Hot PE

    “Home treatment of patients with low-risk pulmonary embolism with the oral factor xa inhibitor rivaroxaban: prospective management trial”

    Para mais informações:



    • Ensaio clínico EMPHENE

    A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000280-16/PT